📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 19:18
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Q1 Net Profit Grows 60% YoY to ₹1.29 Cr; Revenue Jumps 427% YoY
Worth Investment & Trading Co Ltd reported a significant YoY revenue jump to ₹6.53 Cr in Q1 FY26, up from ₹1.24 Cr in the previous year. Net profit followed suit, rising 60.6% YoY to ₹1.29 Cr, though it remained flat on a QoQ basis compared to March 2026. A critical observation is the massive spike in finance costs to ₹4.54 Cr (from ₹0.04 Cr YoY), indicating a heavily leveraged expansion of the loan book. The company continues to operate with high concentration risk, with the majority of its assets deployed as loans to a single sister concern.
Confidence: HIGH
What changedThe company has significantly scaled its lending operations compared to a year ago, resulting in higher interest income but also a massive increase in borrowing costs.
Why it mattersThe sharp rise in finance costs and flat QoQ profit suggest that while the company is growing its top line, the margins are being squeezed by the cost of capital required to fund its concentrated loan book.
Revenue (Q1 FY26): ₹6.53 CrNet Profit (Q1 FY26): ₹1.29 CrFinance Costs: ₹4.54 CrRevenue vs TTM Revenue: ~50.2%YoY Revenue Growth: 427.6%
📅 Short termThe market may focus on the strong YoY growth figures, but the high interest burden and flat QoQ performance are likely to limit any significant upside.
📈 Long termThe company's structural dependence on a single group entity for 94% of its loan book remains a major long-term risk factor, regardless of quarterly growth.
⚠ Risk flags
- Extreme counterparty concentration (Aarey Drugs)
- High leverage (Debt/Equity of 6.64)
- Sharp increase in finance costs
Key Highlights
Revenue from operations increased 427% YoY to ₹6.53 Cr from ₹1.24 Cr.
Net profit grew 60.6% YoY to ₹1.29 Cr, though it slightly declined from ₹1.30 Cr in the preceding quarter.
Finance costs surged to ₹4.54 Cr, representing 69.5% of the total revenue for the quarter.
Total expenses rose to ₹4.78 Cr from ₹0.15 Cr in the same period last year.
Earnings Per Share (EPS) for the quarter stood at ₹0.035, up from ₹0.02 YoY.
👀 What to Watch
Investors should closely monitor the creditworthiness of Aarey Drugs and Pharmaceuticals, as the company's revenue is almost entirely dependent on this single borrower. Watch for any stabilization in finance costs, which are currently consuming a large portion of operating income.
Q1 Net Profit Up 60% YoY to ₹1.29 Cr; Revenue Surges 427% to ₹6.53 Cr
Worth Investment & Trading Co Ltd reported a sharp increase in Q1 FY27 revenue to ₹6.53 Cr, up from ₹1.24 Cr in the year-ago period. Net profit grew 60% YoY to ₹1.29 Cr, though it remained flat sequentially compared to ₹1.30 Cr in Q4 FY26. A significant concern is the surge in finance costs to ₹4.54 Cr from just ₹0.04 Cr YoY, reflecting the company's high leverage. The company's operations remain entirely focused on interest income, with a high concentration risk involving sister concerns.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing a massive scale-up in interest income and a corresponding jump in borrowing costs.
Why it mattersThe results highlight the company's transition into a more leveraged lending model, but the extreme concentration of the loan book to a single group entity remains a structural risk.
Revenue (Q1 FY27): ₹6.53 CrNet Profit (Q1 FY27): ₹1.29 CrFinance Costs: ₹4.54 CrRevenue vs TTM Revenue: ~50.2%Debt-to-Equity Ratio: 6.64
📅 Short termThe stock may see some interest due to the high YoY revenue growth, but the flat sequential profit and high interest burden may temper gains.
📈 Long termThe long-term outlook is constrained by extreme counterparty risk and high leverage; structural re-rating would require loan book diversification.
⚠ Risk flags
- Extreme client concentration (94% of loans to one entity)
- High Debt-to-Equity ratio (6.64)
- Surging finance costs impacting margins
Key Highlights
Revenue from operations increased 427% YoY to ₹6.53 Cr from ₹1.24 Cr.
Net profit for the quarter stood at ₹1.29 Cr, a 60% increase over ₹0.81 Cr in Q1 FY26.
Finance costs escalated dramatically to ₹4.54 Cr compared to ₹0.04 Cr in the same quarter last year.
Total expenses rose to ₹4.78 Cr from ₹0.15 Cr YoY, primarily driven by interest costs.
Earnings Per Share (EPS) for the quarter was ₹0.035, up from ₹0.02 YoY.
👀 What to Watch
Investors should monitor the financial health of Aarey Drugs and Pharmaceuticals, as 94% of the company's loan book is concentrated there. The high debt-to-equity ratio of 6.64 and rising finance costs require close tracking of interest coverage capabilities.
